Cargando…
Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?
The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing a transition to increasingly long-term settings. Unfortunately, chronic therapy-related adverse health events are an unintended, but not infrequent, outcome of these life-saving ther...
Autores principales: | Pettit, Syril D., Kirch, Rebecca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048033/ https://www.ncbi.nlm.nih.gov/pubmed/32154005 http://dx.doi.org/10.1186/s40959-018-0031-4 |
Ejemplares similares
-
Stakeholder perspectives on addressing adverse events from adjuvant cancer therapy: A qualitative study
por: Pettit, Syril D., et al.
Publicado: (2019) -
Guest Editorial: Toxicogenomics in Risk Assessment: Communicating the Challenges
por: Pettit, Syril D.
Publicado: (2004) -
Effects of Renin‐Angiotensin–Aldosterone System Inhibitors on Long‐Term Major Adverse Cardiovascular Events in Sepsis Survivors
por: Ou, Shu‐Yu, et al.
Publicado: (2021) -
ToxPoint: Health Disparities, COVID-19, and Owning Our Share
por: Pettit, Syril D
Publicado: (2020) -
Long-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study
por: Fidler, M M, et al.
Publicado: (2015)